Skip to main content
. 2005 Jul 20;3:8. doi: 10.1186/1477-9560-3-8

Table 4.

Potential VTE risk factors and risk estimates for VTE (definite and probable) based on 4320 women. Comparative assessment with logistic regression analysis: Odds ratio (OR) and 95% confidence interval (95% CI)

Non-cases Cases Crude OR (95% CI) Adjusted* OR (95% CI)
Non-exposed Exposed Non-exposed Exposed

Demographic data
Age: 30+ years vs. <30 2830 1456 13 21 3.1 (1.6–6.3) 2.4 (1.1–5.3)
BMI: 25+ vs. <25 3199 1076 19 15 2.3 (1.2–4.6) 2.0 (0.9–4.1)
OC use: ever vs never 344 3941 2 32 1.4 (0.3–5.9) 1.3 (0.3–5.8)
Other hormones: ever vs. never 4000 267 31 3 1.4 (0.4–4.8) 0.86 (0.2–2.9)
Smoking: ever vs. never 2006 2278 16 18 1.0 (0.5–1.9) 0.8 (0.4–1.7)
Medical history
Personal history of VTE: yes vs. no 4249 37 30 4 15.3 (5.1–45.9) 6.6 (1.8–24.6)
Family history of VTE: yes vs. no 3816 470 24 10 3.4 (1.6–7.1) 2.4 (1.0–5.4)
Family history of varicous veins: yes vs. no 2384 1902 11 23 2.6 (1.3–5.4) 1.9 (0.8–4.1)
Family history of MI: yes vs. no 3804 482 26 8 2.4 (1.1–5.4) 2.0 (0.8–4.6)
Family history of stroke: yes vs. no 3984 302 29 5 2.3 (0.9–5.9) 1.2 (0.4–3.5)
Laboratory & genetic markers
FVL mutation§: yes 4006 267 29 4 2.1 (0.7–5.9) 2.0 (0.7–6.0)
Prothrombin mutation§: yes 4059 140 29 2 2.0 (0.5–8.5) 2.3 (0.5–10.0)
Protein C deficiency#: yes 4087 194 30 4 2.8 (0.98–8.0) 3.0 (0.9–10.4)
AT deficiency#:yes 4073 209 33 1 0.6 (0.1–4.3) 0.5 (0.1–3.5)
MTHFR§: yes 1784 2415 14 17 0.9 (0.4–1.8) 0.95 (0.5–1.97)

§ homo- and heterozygote together

# definition see methods

* adjusted for all other variables